-
From Hollywood to big time tennis: teen makes US Open debut
-
Man City sign Fernandez, Ndiaye as Premier League clubs set new spending record
-
Man City secure Premier League record deal to sign Fernandez
-
Alcaraz aims to step it up in round two of US Open title defense
-
Kaepernick says NFL 'blackballing me' decade after protest
-
Honduran judge drops corruption charges against ex-leader Hernandez
-
Atletico loan David from Juve, send Lemar to Elche
-
Mudryk joins Spurs on loan from Chelsea after doping ban ends
-
Chelsea 'keeper Sanchez makes deadline-day move to Como
-
What's next after judge strikes down New York's landmark climate fund law
-
Kroenke to buy baseball's Los Angeles Angels: statement
-
Cobolli claws out five-set victory at rain-hit US Open
-
US defends Trump's Venezuela oil deal
-
Ndiaye seizes 'chance of a lifetime' in Man City move
-
OpenAI to launch new model with 'stronger safeguards' after hack
-
Global bond sell-off, surging oil prices send markets into the red
-
Fans mourn 'bittersweet' final Ariana Grande gig in London
-
Zuckerberg, Musk make plea at G20 for more AI data centers
-
Norway's King Haakon VIII swears allegiance to constitution
-
'Discomfort' at G20 finance talks as US hosts Russian minister
-
Syria site infrastructure 'consistent with nuclear reactor': IAEA
-
Man City set to sign Fernandez for record fee, Ndiaye on deadline day
-
Juventus sign Woltemade, Sarr on loan from Premier League
-
Back-to-school in Cuba a grim day with shortages of everything
-
US strikes Iran in latest tit-for-tat attacks
-
Canadian minister says Russia's G20 presence sparked 'discomfort'
-
China's Xi arrives in Egypt as US sanctions threat looms over Iran links
-
IMF reaches agreement with Senegal on new $2.2 bn loan programme
-
Car bomb at Colombian police station kills one, injures 11
-
Germany blames Russia for airport drone incident, hits back with sanctions
-
Rain delays start of play on US Open
-
Iran president urges return to truce, hails Russian support
-
Man City agree blockbuster deal to sign Chelsea star Fernandez: reports
-
Aster and World Liberty Financial Launch USD1 RWA Boost: Phase 1, Offering 125M $WLFI + 6.25M USD1 in Rewards
-
Alkemya Metacore Secures $50M via Tokenised Equity to Scale Nickel Energy and Security Tech
-
Tronchon sprints to Vuelta stage 10 win, Mas keeps red jersey
-
Man City chase Fernandez, Arsenal sell Jesus on deadline day
-
Germany defender Rudiger announces international retirement
-
EU says Russian 'hybrid attacks' won't halt aid to Ukraine
-
Musk defends AI data centers, slams EU rules at G20
-
Explosives used in sabotage attack on German power lines
-
Activists blame Kenya for Ugandan opposition figure's plight
-
Nepali families hold symbolic funerals for missing after floods
-
Iran president offers US olive branch, hails Russian support
-
Newcastle sign Lille forward Fernandez-Pardo
-
TrustFinance Community Choice Awards 2026 Opens Global Voting
-
Even at Elysee, phones are handed in, Macron tells French pupils
-
Nepal disaster a climate 'warning signal': foreign minister
-
Chelsea agree to sign Atalanta's Ahanor, with Palace loan for this season
-
France winger Diaby returns to Leverkusen until 2031
Med-X, Inc. Launches Regulation A+ Public Offering to Advance Scientifically Validated, Eco-Friendly Professional Pest Control and Pain Management Solutions
LOS ANGELES, CA / ACCESS Newswire / May 30, 2025 / Med-X, Inc., a leading pioneer of eco-friendly pest control and wellness solutions, announces the launch of a Regulation A+ equity financing round, aiming to raise up to $10 million through the sale of common stock at $4.00 per share with a $600 minimum. This public offering is open to most individuals aged 18 and over, providing an opportunity to invest directly in Med-X via the company's crowdfunding portal (the "Public Offering").
At the forefront of Med-X's multiple product offerings is the flagship product line Nature-Cide, an eco-friendly pest control solution derived from various natural essential oils. The ingredients in Nature-Cide formulations have been scientifically recognized for their insecticidal properties. A 2019 non-sponsored study published in the Florida Journal of Mosquito Control found that a Nature-Cide formulation containing clove and cottonseed oils was more effective against adult mosquitoes than three synthetic pyrethroid-based chemical products that are commonly used by professional pest control applicators for mosquito control globally.
Further research underscores the efficacy of these types of essential oils in pest management operations. A 2024 article in the journal Agriculture highlights the biocidal, repellent, and antifeedant effects of essential oils, noting their potential as natural alternatives to synthetic pesticides. Med-X is strategically positioned at the intersection of rising consumer demand for sustainable and chemical-free solutions in industries ranging from professional pest control and agriculture to public health and disaster relief. The Nature-Cide product line offers unique proprietary, minimum-risk pesticide solutions that are state EPA-registered and widely adopted by professionals and consumers alike. With a variety of verified consumer reviews on Amazon Prime, the brand continues to demonstrate a broad and strong product-market fit.
Med-X continues to expand Nature-Cide's global footprint, with recent product placements in Thailand, Singapore, and New Zealand. The company is actively pursuing registrations in multiple Asian countries, Australia, the UAE, Saudi Arabia, and South America - collaborating with international distributors such as Ensystex and Anasac. In North America, distribution partnerships with Target Specialty Products, Veseris, and Site-One are helping to facilitate future market penetration in Canada, the Caribbean, and Central America.
CEO Matthew Mills emphasizes that the Regulation A+ public offering should enable Med-X to accelerate growth and pursue a direct listing on a national stock exchange, with aspirations to join the NASDAQ under the reserved symbol "MXRX." The Company plans to engage with the investment community through presentations at various investor conferences, supported by strategic partnerships with investor relations firm MZ Group and investment bank Maxim Group.
Med-X remains committed to delivering sustainable, long-term value to shareholders by advancing natural, scientifically supported pest control pain management solutions that prioritize safety and environmental responsibility as well as sustainability.
About Med-X, Inc.
Med-X, Inc. is an innovator in minimum-risk pest control and wellness products, dedicated to developing safe, effective, and environmentally friendly solutions. The company's flagship Nature-Cide products are designed to be safe for use around people, pets, and the environment when used as directed. They are free from harmful synthetic chemicals, offering a responsible and sustainable choice for pest control in residential, commercial, and agricultural settings. The products are also non-flammable and manufactured in the USA, adhering to stringent quality controls.
For more information, please visit www.medx-rx.com.
Investor Relations Contact:
Lucas Zimmerman
Managing Director
MZ Group - MZ North America
262-357-2918
[email protected]
SOURCE: Med-X, Inc.
View the original press release on ACCESS Newswire
A.Moore--AT